PreventT2 Together: Examining the Efficacy of Couple-based Lifestyle Intervention to Prevent Type 2 Diabetes
University of Utah · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06690788
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 324
- US sites recruiting
- 1
- Study start
- March 6, 2025
- Record last updated
- October 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Nearly half of adults in the United States have or are at risk of developing type 2 diabetes. The overall goal of this community-engaged research is to examine the efficacy of an innovative couple-based lifestyle intervention to prevent type 2 diabetes that is applicable to a broad range of partnered adults in the United States. By simultaneously targeting lifestyle and perceived support from romantic partners, there is a high likelihood of creating lasting changes in both
Being studied: Individual intervention condition (PreventT2); Couple-based intervention condition (PreventT2 Together; couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP)
Conditions: Prediabetic State; Life Style; Intervention Study; Social Support; Physical Activity; Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- "Target partner" is eligible for the National DPP per CDC eligibility requirements:
- BMI ≥ 25 kg/m² (≥ 23 kg/m² if Asian American), and
- Do not have a diagnosis of type 1 or type 2 diabetes, and
- Not currently pregnant, and
- High risk for type 2 diabetes based on: (i) CDC Prediabetes Risk Test score ≥ 5, (ii) clinically diagnosed Gestational Diabetes during a previous pregnancy (for women), or (iii) a blood test result indicative of prediabetes in the past year (i.e., fasting blood glucose 100-125 mg/dl; plasma glucose 140-199 mg/dl measured 2 hours after a 75 g glucose load; or HbA1c 5.7%-6.4%).
- The couple has lived together for 1+ years.
- Both partners are willing to participate in the research.
- Both partners are at least 18 years old.
- Both partners are fluent in English.
EXCLUSION CRITERIA
- "Supporting partner" has a diagnosis of Type 2 Diabetes.
- Either partner:
- Has a diagnosis of another chronic disease (unless no major events/changes for 3+ months), or
- Is currently on medication or engaged in lifestyle intervention for prediabetes or obesity, or
- Has previously participated in the National DPP, or
- Reports discomfort participating in a lifestyle program with their partner, or
- Reports a low level of relationship commitment (i.e., "4" or lower on a scale from 1 (do not agree at all) to 7 (agree completely) on the item "I want this relationship to stay strong no matter what rough times we encounter."; Owen et al., 2011).
Recruiting US locations
University of Utah
Salt Lake City, UT 84112
Site contact: Elizabeth Z Beaulieu, BS · 801-696-3757 · heartlab@psych.utah.edu
Study contacts (from the official record)
- Elizabeth Z Beaulieu, B.S. · 801-696-3757 · elizabeth.beaulieu@psych.utah.edu
- Katherine JW Baucom, PhD · katherine.baucom@psych.utah.ed
Similar studies in Utah
All weight loss studies in Utah →- RecruitingHealthy volunteersPhase 1
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Gilead Sciences
- Location
- Salt Lake City, UT + 2 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
Ascletis Pharma (China) Co., Limited
- Location
- Salt Lake City, UT + 1 other US site
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- South Jordan, UT + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Salt Lake City, UT + 43 other US sites
- Eligibility basics
- Ages 18+